Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Vaccines

Free Subscription 26.01.2026 3 BMJ 1 Clin Infect Dis 4 J Infect Dis 1 J Pediatr 1 Lancet 3 Nat Med 1 PLoS Med 2 PLoS One 2 Proc Natl Acad Sci U S A 27 Vaccine

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMJ

1. IACOBUCCI G
   Childhood vaccinations: Falling rates in England are "national disgrace," say MPs.
   BMJ. 2026;392:s139.
   PubMed        
   
   
2. TANNE JH
   US medical groups file lawsuit to stop RFK Jr's vaccine changes.
   BMJ. 2026;392:s145.
   PubMed        
   
   
3. MAHASE E
   UK is better protected than US against vaccine politicisation-but is not immune, top adviser warns.
   BMJ. 2026;392:s60.
   PubMed        
   
   

   
   Clin Infect Dis

4. WINOKUR P, Diya O, Fitz-Patrick D, Dever M, et al
   Safety and Immunogenicity of a Fourth Dose of Omicron-BA.1-Adapted BNT162b2 COVID-19 Vaccines in Adults 18?55 Years Old.
   Clin Infect Dis. 2026 Jan 21:ciag026. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Infect Dis

5. ZHANG X
   How "Enhanced" Are Enhanced Influenza Vaccines for Neuraminidase? Antigen Content and Baseline Immunity Revisited.
   J Infect Dis. 2026 Jan 23:jiag042. doi: 10.1093.
   PubMed        
   
   
6. CHATURVEDI AK, Haber G, Graubard BI, Cheung LC, et al
   Risk-based prophylactic HPV vaccination of heterosexual US men aged 27 to 45 years for prevention of oropharyngeal cancer.
   J Infect Dis. 2026 Jan 20:jiag038. doi: 10.1093.
   PubMed         Abstract available
   
   
7. SONG EM, An HM, Kim SE, Shim KN, et al
   Coronavirus Disease 2019 Risk in Patients With Autoimmune Diseases Using Biologics or Small Molecules: A Population-Based Cohort Study.
   J Infect Dis. 2026;233:137-147.
   PubMed         Abstract available
   
   
8. BIDARI S, Yuan H, Yang W
   Assessing the Transmissibility and Outbreak Risk of Measles in the United States, 2024-2030.
   J Infect Dis. 2026;233:132-136.
   PubMed         Abstract available
   
   

   
   J Pediatr

9. MCCLURE DL, Hanson KE, Sundaram ME, Kieke BA, et al
   Incident Epilepsy and Vaccination Status or Vaccine Aluminum Exposure in Children Under Age 4.
   J Pediatr. 2026 Jan 19:115004. doi: 10.1016/j.jpeds.2026.115004.
   PubMed         Abstract available
   
   

   
   Lancet

10. POLLARD AJ, Plotkin S
    A risk to child health: confusion and concern over changes to US vaccine policy.
    Lancet. 2026 Jan 20:S0140-6736(26)00090-5. doi: 10.1016/S0140-6736(26)00090.
    PubMed        
    
    

    
    Nat Med

11. KIM K, Title B, Kipnis J
    Placebo effect influences vaccine responses.
    Nat Med. 2026 Jan 19. doi: 10.1038/s41591-025-04168.
    PubMed        
    
    
12. LUBIANIKER N, Koren T, Djerasi M, Sirotkin M, et al
    Upregulation of reward mesolimbic activity and immune response to vaccination: a randomized controlled trial.
    Nat Med. 2026 Jan 19. doi: 10.1038/s41591-025-04140.
    PubMed         Abstract available
    
    
13. WONG GL, Yuen MF, Lin B, Douglas MW, et al
    Elebsiran and PEG-IFNalpha for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial.
    Nat Med. 2026;32:151-159.
    PubMed         Abstract available
    
    

    
    PLoS Med

14. MONOI A, Endo A, Procter SR, Leuba SI, et al
    The benefits and risks of maternal RSV vaccination on mortality in South Africa: A modeling study.
    PLoS Med. 2026;23:e1004625.
    PubMed         Abstract available
    
    

    
    PLoS One

15. HOU Y, Chen H, Jiang Y, Huang H, et al
    Shifting epidemiological patterns and strain replacement of hand, foot, and mouth disease in southern China, 2009-2022: A longitudinal study.
    PLoS One. 2026;21:e0341302.
    PubMed         Abstract available
    
    
16. SULIS G, Maredia N, Wolfson C, Basta NE, et al
    Changes in pneumococcal vaccine coverage in the Canadian Longitudinal Study on Aging (CLSA): An analysis based on the 2018-2021 follow-up 2 survey.
    PLoS One. 2026;21:e0338213.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

17. GERVAIS A, Bastard P, Zhang Q, Jaffar-Bandjee MC, et al
    Type I IFN autoantibodies underlie chikungunya live-attenuated vaccine encephalitis.
    Proc Natl Acad Sci U S A. 2026;123:e2532212123.
    PubMed         Abstract available
    
    
18. TE N, Chin AWH, Gu H, Zhirong Jia J, et al
    Broad beta-CoV immunity and transmission blockade by a single-dose live-attenuated vaccine with atypical codon usage.
    Proc Natl Acad Sci U S A. 2026;123:e2518645123.
    PubMed         Abstract available
    
    

    
    Vaccine

19. WOO EJ
    Adjuvanted recombinant zoster vaccine and live attenuated zoster vaccine are vastly different.
    Vaccine. 2026 Jan 23:128272. doi: 10.1016/j.vaccine.2026.128272.
    PubMed        
    
    
20. STUART R, Theopold N, Miall N, Kobayashi E, et al
    The role of HPV single-dose vaccination in expanding access in GAVI-supported countries during a period of supply constraints.
    Vaccine. 2026;75:128187.
    PubMed         Abstract available
    
    
21. ADAM A, Lee C, Jones MC, Harrington BR, et al
    VSA-2-, a novel plant-derived adjuvant for SARS-CoV-2 subunit vaccine.
    Vaccine. 2026;75:128255.
    PubMed         Abstract available
    
    
22. LI J, Kyaw PE, Tan C, Wen K, et al
    Development of duck hepatitis A virus type 1 attenuated vaccine E23-SP80 and its protective efficacy evaluation against DHAV-1 infection in ducks.
    Vaccine. 2026;75:128258.
    PubMed         Abstract available
    
    
23. LANGLEY JM, Sadarangani M, Ockenhouse C, Barreto L, et al
    Safety and immunogenicity of a 25-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive healthy adults: Results from 2 randomised, controlled clinical trials.
    Vaccine. 2026;75:128236.
    PubMed         Abstract available
    
    
24. VATTOTH AL, Hayney MS, Forati AM, Warren B, et al
    Immunogenicity and safety of a recombinant spike protein COVID vaccine in patients with inflammatory bowel disease and transplant recipient.
    Vaccine. 2026;75:128208.
    PubMed         Abstract available
    
    
25. JEONG O, Choi W, Ahn H, Lee S, et al
    Bromelain-cleaved hemagglutinin production from cell culture-derived influenza viruses enhances vaccine potency quantification by single radial immunodiffusion assay.
    Vaccine. 2026;75:128235.
    PubMed         Abstract available
    
    
26. YESENIA RODRIGUEZ-TANTA L, Delgado-Escalante R, Del Pilar Solis-Yucra T, Rojas EC, et al
    Post-marketing safety surveillance of the BBIBP-CorV (Sinopharm) COVID-19 vaccine in Peruvian healthcare workers: A retrospective analysis of a Pharmacovigilance Center.
    Vaccine. 2026;75:128227.
    PubMed         Abstract available
    
    
27. YIGIT I, Stoner MCD, Muessig KE, Hightow-Weidman LB, et al
    Pathways to COVID-19 vaccine initiation: The roles of medical mistrust, conspiracy beliefs, hesitancy, and confidence among black young adults.
    Vaccine. 2026;75:128253.
    PubMed         Abstract available
    
    
28. SHI L, Chen J, Li H, Yan X, et al
    Safety, immunogenicity, and lot consistency of a 13-valent pneumococcal conjugate vaccine in Chinese children aged 2-5 years: A phase III study.
    Vaccine. 2026;75:128244.
    PubMed         Abstract available
    
    
29. NIKHAB A, Patel T, Rooney G, Wasti S, et al
    Assessing the potential impact of the 20-valent (PCV20) and an adult 21-valent (aPCV21) pneumococcal conjugate vaccine on invasive pneumococcal disease in England.
    Vaccine. 2026;75:128246.
    PubMed         Abstract available
    
    
30. HANDY AB, Ren B, Seidman LC, Granger SW, et al
    Inflammatory mechanisms of menstrual cycle changes following COVID-19 vaccination in adolescents.
    Vaccine. 2026;75:128226.
    PubMed         Abstract available
    
    
31. SIM SY, Silal S, Hutubessy RC, Bar-Zeev N, et al
    Advancing the use of vaccine impact modeling for immunization decisions in low- and middle-income countries.
    Vaccine. 2026;75:128239.
    PubMed        
    
    
32. CHELLAPPAN G, Seal F, Balasundaram WU, Zhao Y, et al
    Preclinical immunogenicity studies of Haemophilus influenzae type a glycoconjugate vaccine.
    Vaccine. 2026;75:128242.
    PubMed         Abstract available
    
    
33. SIGAUQUE B, Vilanculos L, Chauque A, Moiane B, et al
    Effectiveness of 10-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia and invasive pneumococcal disease among young children in Mozambique.
    Vaccine. 2026;75:128237.
    PubMed         Abstract available
    
    
34. WU B, Cheng T, Zhang Y, Kezhong A, et al
    Adult and maternal pertussis vaccination in China: intention, preferences, and pricing implications from a discrete choice experiment.
    Vaccine. 2026;75:128243.
    PubMed         Abstract available
    
    
35. CHANGALUCHA J, Ferguson E, Luka MM, Lushasi K, et al
    Comparative effectiveness and cost-effectiveness of policies for provisioning rabies post-exposure vaccines.
    Vaccine. 2026;74:128178.
    PubMed         Abstract available
    
    
36. AYABINA D, Stoecker C, Cho BH, Prasad N, et al
    Public health impact and cost-effectiveness of 20-valent pneumococcal conjugate vaccine use among children in the United States.
    Vaccine. 2026;74:128212.
    PubMed         Abstract available
    
    
37. KLING K, Falman A, Branke L, Ramharter M, et al
    Vaccination against chikungunya - a systematic review on the immunogenicity, tolerability, and safety of the live-attenuated vaccine (LAV) Ixchiq and the virus like particle (VLP) vaccine Vimkunya.
    Vaccine. 2026;75:128251.
    PubMed         Abstract available
    
    
38. SHUAI W, Sun Q, Li J, Shen W, et al
    Needle-free intradermal delivery of a recombinant PRRSV-vectored CSFV E2 vaccine enhances humoral immunity and growth performance in piglets.
    Vaccine. 2026;75:128247.
    PubMed         Abstract available
    
    
39. FAIJUE DD, Bouaddi O, Mackey K, Deal A, et al
    Strategies, interventions, and uptake of catch-up vaccination among adolescent and adult migrants, refugees, and internally displaced persons (IDPs) in low- and middle-income countries (LMICs): A systematic review.
    Vaccine. 2026;75:128249.
    PubMed         Abstract available
    
    
40. FLOROS L, Johnson KD, Tsoumani E
    Serotype-specific incidence and comparative vaccine coverage of invasive pneumococcal disease among adults >/=65 years of age in European countries from 2011 to 2023.
    Vaccine. 2026;75:128181.
    PubMed         Abstract available
    
    
41. LISTER H, Farquharson K, Seale H, Smith LE, et al
    Erratum to "A systematic review of the impact of vaccine reactogenicity on willingness to accept influenza vaccination in adults" [Vaccine 74 (2026) 128195].
    Vaccine. 2026;75:128252.
    PubMed        
    
    
42. MVUNDURA M, Slavkovsky R, Dagnew B, Hunduma A, et al
    Evaluating the delivery costs and operational context of a single-dose human papillomavirus (HPV) vaccine regimen administered to a multi-age cohort of adolescent girls in Ethiopia.
    Vaccine. 2026;75:128248.
    PubMed         Abstract available
    
    
43. BARBEY FA, Otth M, Kroiss S, Drozdov D, et al
    Adherence to national vaccination guidelines among pediatric cancer patients: a retrospective study from two tertiary care centers in Switzerland.
    Vaccine. 2026;75:128265.
    PubMed         Abstract available
    
    
44. TEMBO G, Hoving D, de Kroon AC, Chimgoneko L, et al
    13-valent pneumococcal conjugate vaccine-induced B cells produce serotype 6B but not serotype 3 capsule-specific IgG antibodies in young Malawian adults.
    Vaccine. 2026;75:128269.
    PubMed         Abstract available
    
    
45. CONTARINO F, Fiorilla C, Bella F, Orsi A, et al
    Exploring regional variations in the provision of influenza vaccination in Italy.
    Vaccine. 2026;75:128266.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.